Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging

Jung, Jo Sung; Choi, Yoon Seong; Ahn, Sung Soo; Yi, Seong; Kim, Se Hoon; Lee, Seung Koo

doi:10.1007/s00234-019-02154-8

Cited by 49 publications

(63 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the boundaries of the tumor are ill-defined, and mild peritumoral edema may be notable. These radiological features are consistent with a high-grade glioma (4,11,12). Some scholars summarized that H3 K27M-mutant DMGs occurring in the cervical spinal cord usually showed uniform enhancement (13).…”

Section: Discussionsupporting

confidence: 63%

Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient

Cheng

Zhang

et al. 2021

Front. Surg.

View full text Add to dashboard Cite

Background: Diffuse midline glioma (DMG) with histone H3 K27M mutation is a recently identified entity documented in the 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System. Spinal cord DMGs with H3 K27M-mutant are commonly reported in adults. Herein, we reported a pediatric patient with spinal cord H3 K27M-mutant DMG.Case Report: A 7-year-old girl with 1-month history of neck pain and 3-week history of progressive weakness in the right hand was presented. Spinal magnetic resonance imaging showed an intramedullary lesion with slight enhancement at the C2-7 levels. With intraoperative neuroelectrophysiological monitoring, the lesion was subtotally resected. Histopathological examination revealed a DMG with histone H3 K27M mutation corresponding to WHO grade IV. Postoperatively, the neck pain was relieved, and the upper-extremity weakness remained unchanged. Oral temozolomide was administrated for 7 months, and radiotherapy was performed for 22 courses. After an 18-month follow-up, no tumor recurrence was noted.Conclusion: Spinal cord H3 K27M-mutant DMGs are extremely rare in pediatric patients. Preoperative differential diagnosis is challenging, and surgical resection with postoperative chemoradiotherapy may be an effective treatment.

show abstract

Section: Discussionsupporting

confidence: 63%

Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient

Cheng

Zhang

et al. 2021

Front. Surg.

View full text Add to dashboard Cite

show abstract

“…Regarding its specificity and sensitivity, they are calculated to be at least 88.2% and 95% respectively. 14 It is now deemed 15 that aggressive surgical excision is the most effective therapeutic strategy for most spinal cord gliomas. With constant advances in imaging techniques and increasingly clear operating microscopes, an increasing number of tumors can be detected at an early stage.…”

Section: Discussionmentioning

confidence: 99%

“…Regarding its specificity and sensitivity, they are calculated to be at least 88.2% and 95% respectively. 14 …”

Section: Discussionmentioning

confidence: 99%

“…As indicated by postoperative MRI, over 5% of the tumors are left behind. 6 In conformity with therapeutic response evaluation standards of the spinal cord glioma, 7 clinical efficacy can be classified into four grades of complete remission (CR), partial remission (PR), stabilization (SD) and progression (PD). On this basis, differences in clinical efficacy of both groups are comparatively analyzed.…”

Section: Surgical Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Application evaluation of intraoperative ultrasound combined with neuro electrophysiological detection in the spinal cord glioma surgery

Liu

Liang

et al. 2021

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To observe application values of intraoperative ultrasound combined with neuro electrophysiological detection in the spinal cord glioma surgery. Methods: Sixty patients with spinal cord glioma hospitalized in Baoding First Central Hospital from January 2016 to January 2018 were selected, randomly divided into two groups by the random number table method, with 30 cases of each group. PASS software was used to calculate the sample size. The control group was treated with traditional microsurgery, while the experimental group was treated with intraoperative ultrasound combined with neuro electrophysiological testing. The operation time, intraoperative blood loss, postoperative hospital stays, degree of tumor resection, clinical efficacy, recovery of neurological function, recovery of health status, quality of life score, and 2-year recurrence rate of the two groups of patients were observed and compared. Results: The operation time of the experimental group was longer than that of the control group, and the postoperative hospital stay was shorter than that of the control group. The complete tumor resection rate, complete remission rate and postoperative scale scores of the experimental group were significantly higher than those of the control group, while the recurrence rate within two years was significantly lower than that of the control group. The above differences were statistically significant (p<0.05). Conclusions: Intraoperative ultrasound combined with neuro-electrophysiological detection for spinal glioma has more adequate protection of nerve function, high clinical complete remission rate, more thorough tumor resection, and lower recurrence rate than traditional microsurgery, which is worthy of clinical application. doi: https://doi.org/10.12669/pjms.37.3.3638 How to cite this:Li X, Liu ZJ, Liang L, Dong HQ. Application evaluation of intraoperative ultrasound combined with neuro electrophysiological detection in the spinal cord glioma surgery. Pak J Med Sci. 2021;37(3):---------. doi: https://doi.org/10.12669/pjms.37.3.3638 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

“…While recent advancements in the understanding of the pathology of diffuse midline gliomas and identification of targetable pathways have been dependent on tissue sampling, groups are currently investigating noninvasive methods for evaluating mutational status in these tumors via imaging [45,46] or sequencing of circulating tumor DNA [47,48]. However, biopsy remains the gold standard for clinical trial consideration.…”

Section: Discussionmentioning

confidence: 99%

Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section

et al. 2020

View full text Add to dashboard Cite

Purpose Diffuse midline gliomas are rare midline CNS malignancies that primarily affect children but can also affect adults. While radiation is standard treatment, prognosis remains fatal. Furthermore, due to its sensitive anatomic location, many physicians have been reluctant to perform biopsies without potential for improved prognosis. However, recent advancements in molecular-targeted therapeutics have encouraged greater tissue sampling. While the literature reflects this progress, the landscape of how clinicians actually manage these patients remains unclear. Our goal was to assess the attitudes of current practicing neurosurgical oncologists towards management of adult diffuse midline gliomas, reasons behind their practices, and factors that might influence these practices. Methods We created and distributed a survey with 16 multiple choice and open-ended questions to members of the Tumor Section of the Congress of Neurological Surgeons. Results A total of 81 physicians responded to the survey. Although time since training and volume of glioma patients did not significantly affect the decision to consider clinical trials or to offer biopsy, those that operated on fewer gliomas (< 25/ year) were more likely to cite surgical morbidity as the primary reason not to biopsy these midline locations. Further, surgeons with access to more advanced molecular testing were significantly more likely to consider clinical trial eligibility when offering biopsies. Conclusion Factors that affect the management of diffuse midline gliomas and the role of biopsy are relatively uniform across the field, however, there were a few notable differences that reflect the changes within the neuro-oncology field in response to clinical trials.

show abstract

Differentiation between spinal cord diffuse midline glioma with histone H3 K27M mutation and wild type: comparative magnetic resonance imaging

Cited by 49 publications

References 20 publications

Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient

Spinal Cord Diffuse Midline Glioma With Histone H3 K27M Mutation in a Pediatric Patient

Application evaluation of intraoperative ultrasound combined with neuro electrophysiological detection in the spinal cord glioma surgery

Variations in attitudes towards stereotactic biopsy of adult diffuse midline glioma patients: a survey of members of the AANS/CNS Tumor Section

Contact Info

Product

Resources

About